IRIDEX (NASDAQ:IRIX) Major Shareholder Shih-Yao David Lin Acquires 24,626 Shares of Company Stock

IRIDEX Corporation (NASDAQ:IRIX) major shareholder Shih-Yao David Lin purchased 24,626 shares of the business’s stock in a transaction that occurred on Friday, November 14th. The stock was bought at an average price of $0.88 per share, for a total transaction of $21,670.88. Following the purchase, the insider directly owned 808,340 shares in the company, valued at $711,339.20. The trade was a 3.14% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Major shareholders that own 10% or more of a company’s shares are required to disclose their transactions with the SEC.

IRIDEX Stock Up 29.4%

IRIX stock opened at $0.88 on Thursday. The business has a 50 day moving average of $0.73 and a 200 day moving average of $0.95. The firm has a market cap of $15.46 million, a PE ratio of -4.40 and a beta of 0.67. IRIDEX Corporation has a twelve month low of $0.61 and a twelve month high of $1.65.

IRIDEX (NASDAQ:IRIX) last released its earnings results on Tuesday, August 18th. The medical equipment provider reported ($0.07) EPS for the quarter, missing the consensus estimate of ($0.01) by ($0.06). The business had revenue of $12.57 million during the quarter, compared to analyst estimates of $13.59 million. On average, research analysts expect that IRIDEX Corporation will post -0.12 earnings per share for the current fiscal year.

Analyst Ratings Changes

Separately, Weiss Ratings upgraded shares of IRIDEX from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Friday, October 2nd. One analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $3.00.

Institutional Investors Weigh In On IRIDEX

Several institutional investors and hedge funds have recently made changes to their positions in the company. Bank of New York Mellon Corp purchased a new position in IRIDEX in the 2nd quarter worth approximately $29,000. Diversify Advisory Services LLC bought a new position in IRIDEX in the 2nd quarter valued at approximately $30,000. Diversify Wealth Management LLC purchased a new stake in IRIDEX during the 1st quarter valued at $35,000. United Capital Financial Advisors LLC purchased a new stake in IRIDEX during the 2nd quarter valued at $41,000. Finally, Thompson Davis & CO. Inc. boosted its stake in IRIDEX by 66.5% during the 1st quarter. Thompson Davis & CO. Inc. now owns 47,444 shares of the medical equipment provider’s stock valued at $48,000 after purchasing an additional 18,944 shares during the last quarter. Institutional investors own 20.10% of the company’s stock.

Key Stories Impacting IRIDEX

Here are the key news stories impacting IRIDEX this week:

• Positive Sentiment: SEC disclosures show Lin made dozens of purchases totaling substantial share amounts, including transactions of 50,000 shares at $0.99, 40,114 shares at $1.00 and 80,000 shares at $1.00. The repeated buying and growing ownership stake may be interpreted as a sign of confidence in IRIDEX’s long-term prospects. IRIDEX major shareholder buys 50,000 shares
• Positive Sentiment: The filings also include purchases at prices ranging from approximately $0.84 to $1.52, with several individual transactions valued between roughly $20,000 and $58,000. This broad pattern of buying, rather than a single isolated trade, likely attracted speculative interest in the thinly traded stock. IRIDEX major shareholder acquires stock
• Neutral Sentiment: Investors should note that most purchases occurred weeks or months earlier, from March through June and in prior reporting periods; the disclosures are new, but the buying itself is not. The reports therefore provide sentiment support rather than evidence of a new operating development or immediate improvement in revenue and earnings.
• Neutral Sentiment: Trading in IRIX was temporarily halted under a Limit Up-Limit Down (LULD) pause, indicating that the stock’s rapid move exceeded permitted price bands. This highlights significant volatility and the potential for sharp reversals once trading resumes.

IRIDEX Company Profile

IRIDEX Corporation (NASDAQ: IRIX) develops and sells ophthalmic laser systems and related delivery devices used in the treatment of eye diseases. Its products are designed primarily for ophthalmologists treating glaucoma and retinal disorders, including diabetic retinopathy and other conditions affecting the retina.

The company’s portfolio includes laser systems such as the Cyclo G6 glaucoma laser platform and the IQ series of retinal photocoagulation lasers. IRIDEX also offers specialized probes and other delivery devices, including MicroPulse and transscleral cyclophotocoagulation technologies, which are intended to provide targeted treatment while limiting exposure to surrounding tissue.

Founded in 1989 and headquartered in Mountain View, California, IRIDEX serves eye-care professionals through a combination of direct sales and distributor relationships in the United States and international markets.